Novavax (NVAX) closed the most recent trading day at $14.06, moving +1.99% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.25% for the day. Meanwhile, the Dow gained 0.77%, and the Nasdaq, a tech-heavy index, lost 0.79%. Heading into today, shares of the vaccine maker had lost 12.2% over the past month, lagging the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59% in that time. The investment community will be closely monitoring the performance of ...

Novavax (NVAX) submitted an application to the FDA, seeking to amend its Emergency Use Authorization (EUA) and update its protein-based COVID-19 vaccine for the upcoming fall season. While this updated vaccine has been formulated to target the JN.1 variant, management claims that the vaccine has also been shown to be effective against the current circulating strains, including KP.2 and KP.3. Subject to necessary permissions from the FDA and CDC, Novavax intends to market this updated COVID-19 vaccine in pre ...

Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available in the U.S. Novavax's filing is aligned with FDA, EMA and WHO global recommendations on vaccine composition Novavax intends to have its vaccine in pre-filled syringes available in the U.S. for immediate release post- authorization and following recommendation by the U.S. CDC GAITHERSBURG, Md., June 14, 2024 /PRNewswire ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this vaccine maker have returned +104.6% over the past month versus the Zacks S&P 500 composite's +3.3% change. The Zacks Medical - Biomedical and Genetics industry, to which Novavax belongs, has gained 0.9% over this period. Now the key question is: Where could the stock be headed in the near term? Althou ...

文章核心观点 - 公司在过去3年间成功推出首款商业化产品并建立了稳定的技术平台 [4][5][7] - 公司通过重组债务和降低运营成本,大幅改善了财务状况 [6] - 公司与Sanofi建立了战略合作伙伴关系,获得了多层面的潜在价值 [8][9][10][31][32][33][34] - 公司自身也在开发新的疫苗产品,包括流感疫苗和流感新冠联合疫苗,预计将于明年内完成临床试验 [11][45][46][47] - 公司未来将专注于研发,并寻求更多的业务合作机会来充分发挥自身技术平台的价值 [12][36][37] 公司情况 - 公司在过去3年间成功推出首款商业化产品并建立了稳定的技术平台 [4][5][7] - 公司通过重组债务和降低运营成本,大幅改善了财务状况 [6] - 公司与Sanofi建立了战略合作伙伴关系,获得了多层面的潜在价值 [8][9][10][31][32][33][34] - 公司未来将专注于研发,并寻求更多的业务合作机会来充分发挥自身技术平台的价值 [12][36][37] 产品管线 - 公司自身也在开发新的疫苗产品,包括流感疫苗和流感新冠联合疫苗,预计将于明年内完成临床试验 [11][45][46][47] 商业化策略 - 公司与Sanofi建立了战略合作伙伴关系,获得了多层面的潜在价值 [8][9][10][31][32][33][34] - 公司未来将专注于研发,并寻求更多的业务合作机会来充分发挥自身技术平台的价值 [12][36][37]

Vaccine maker Novavax (NASDAQ:NVAX) saw its shares jump 18% on June 5 and another 20% in pre-market trade this morning. NVAX stock is up over 300% year-to-date. Novavax also said it will be able to deliver an updated Covid-19 vaccine in September, made without the use of controversial mRNA technology. More important to investors may be the fact that over 36% of Novavax shares are now being held short, including over half traded off listed exchanges. NVAX stock is due to open today at $24.10 per share, a mar ...

Novavax (NASDAQ:NVAX) is on a recovery trek after collapsing in late 2021. Recently, management said that its latest vaccine version addressing newer Covid-19 subvariants is more effective than older injections. According to a Reuters report, vaccine makers presented animal study data which “showed their 2024-25 shots targeting the JN.1 variant that was dominant earlier this year could neutralize newer subvariants such as KP.2 much better than the older shots.” Novavax and other vaccine developers, includin ...

Shares of COVID-19 vaccine developers rose on Monday after the FDA issued briefing documents for its Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting on Jun 5 to consider the selection of the 2024-2025 formula for COVID-19 vaccines. In this meeting, members of the VRBPAC will discuss whether to update the currently authorized COVID-19 vaccines to target the JN.1 variant. This was also recommended by a World Health Organization (WHO) advisory committee on Apr 26. The FDA pointed o ...

GAITHERSBURG, Md., May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference. Conference Details: Fireside Chat Date: Thursday, June 6, 2024 Time: 12:30 – 12:55 p.m. Eastern Time (ET) Location: New York, NY Moderator: Roger Song, MD, CFA, Equity Research Analyst – Biotechnology Novavax participant:John C. Jacobs, President and Chief Executive ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this vaccine maker have returned +261.3% over the past month versus the Zacks S&P 500 composite's +4.2% change. The Zacks Medical - Biomedical and Genetics industry, to which Novavax belongs, has gained 6.2% over this period. Now the key question is: Where could the stock be headed in the near term? Although medi ...